Gabather
1,645 SEK -1,2%1 investor følger denne virksomhed
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GABA
Daglig lav / høj pris
1,53 / 1,68
SEK
Markedsværdi
29,77 mio. SEK
Aktieomsætning
11,53 t SEK
Volumen
7,2 t
Finanskalender
Delårsrapport
30.05.2024
Generalforsamling
30.06.2024
Delårsrapport
29.08.2024
Delårsrapport
28.11.2024
Årsrapport
27.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 14,5 % | 14,5 % |
Nordnet Pension | 2,6 % | 2,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools